Company profile

Starry Pharmaceutical established in 1997, is a high-tech enterprise specialized in R&D, production and sales of X-CT non-ionic contrast agent series, fluoroquinolones series raw materials and intermediates. And we are one of the largest and most complete enterprises in the domestic generic products of contrast agents, of which the production capacity and output of iohexol APIs rank the forefront in China. "Twelve Five" period, Starry established an intermediate production base in Jiangxi Zhangshu in January 2011--Jiangxi Starry Pharmaceutical Co. Ltd. On 9 March 2016, our company was listed on the Shanghai Stock Exchange, stock code: 603520. In November 2018, we successfully acquired a domestic peer company, Zhejiang Taizhou Hisyn Pharmaceutical Co., Ltd.

Starry adheres to the whole industry chain layout and globalisation development route, and continuously improves the R&D, production and quality systems. In the field of global Iodine contrast agent APIs, we are one of the enterprises that simultaneously possesses registration certificates in China, EU, Japan, India, South Korea, and other countries or regions, and passes the DMF integrity review in the U.S. FDA.

In terms of fluoroquinolones series APIs, Starry is at the leading level in the field of impurity separation and synthesis of levofloxacin series products, and is one of the largest levofloxacin series manufacturers in China.

1997 Year

Establishment time

603520

Securities code

2000 Individual

Excellent staff

4 Bases

R & D and production

Starry is committed to the sustainable development strategy of X-ray contrast media, attaches great importance to independent research and development capabilities, and has achieved abundant results. The company's research and development projects for its related products have been honored with provincial and national awards on multiple occasions. Additionally, the company has garnered over 400 awards of various magnitudes since its inception. We have established a charitable fund totaling 45 million yuan and contributed more than 20 million yuan to various sectors of society.

In 2020, Starry achieved commercial production of FDF and won the national fifth and seventh batch of centralized procurement in 2021 and 2022. At present, we have become the main supplier of FDF in China, covering nearly 30 provinces and more than 3000 hospitals.

Deeming the philosophy of "gathering life energy and caring for human health"and the development policy of "replacing imports with specialized products and filling domestic gaps", the company has been continuously devoting itself to the R&D of new drugs, based in China, looking globally and makes contributions to the medical and health industry for all mankind.